Search
Ranosidenib
go.drugbank.com/drugs/DB21727InvestigationalRanosidenib is under investigation in clinical trial NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia).
Inactivated SARS-Cov-2 Vaccine
go.drugbank.com/drugs/DB15862InvestigationalDeveloped by Sinopharm's Wuhan Institute of Biological Products co., this vaccine consists of the WIV04 strain of SARS-CoV-2. … [A220158] Currently, the vaccine is being tested in Phase 3 clinical trial in Abu Dhabi (ChiCTR2000034780).[A219758]
2'-fluoro-5-ethylarabinosyluracil
go.drugbank.com/drugs/DB13030Investigational2'-fluoro-5-ethylarabinosyluracil (FAU) has been used in trials studying the treatment of Small Intestine Lymphoma, Stage IV Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Splenic Marginal Zone Lymphoma
CDX-1135
go.drugbank.com/drugs/DB17607InvestigationalCDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex).
SIG-207
go.drugbank.com/drugs/DB18547ExperimentalSIG-207 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express Human alpha-galactosidase A (alpha-Gal A), encapsulated within two-layer modified
Oxabolone cipionate
go.drugbank.com/drugs/DB13185ExperimentalOxabolone cipionate is the C17β cypionate ester and a prodrug of [DB01500]. A synthetic anabolic-androgenic (AAS) steroid, it is a derivative of 19-nortestosterone (nandrolone).
Synonyms: Cipionato de oxabolonaTralesinidase alfa
go.drugbank.com/drugs/DB17657InvestigationalIt is being investigated for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome B.[A258828]
NSI-566
go.drugbank.com/drugs/DB17954InvestigationalDeveloped by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).[L47097]
Growth hormone-releasing peptide 1
go.drugbank.com/drugs/DB19259InvestigationalGrowth hormone-releasing peptide 1 is under investigation in clinical trial NCT00381602 (A Phase II, Randomized, Cross-over, Vehicle-controlled, Double-blind, Multicenter Study of the Safety, Pharmacodynamics
(R)-warfarin
go.drugbank.com/drugs/DB08496ExperimentalS-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.[A1038]